VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

26 A EGIS C APITAL C ORP. Rating and Price Target History for: VistaGen Therapeutics, Inc. (VTGN) as of 10-07-2020 2.50 2.00 1.50 1.00 0.50 0.00 Q3 2018 Q1 Q2 Q3 2019 Q1 Q2 Q3 2020 Q1 Q2 Q3 2021 Powered by: BlueMatrix Investment Banking Services/Past 12 Mos. Rating Percent Percent BUY [BUY] 91.30 38.10 HOLD [HOLD] 8.70 33.33 SELL [SELL] 0.00 0.00 Meaning of Ratings A) A Buy rating is assigned when we do not believe the stock price adequately reflects a company's prospects over 12-18 months. B) A Hold rating is assigned when we believe the stock price adequately reflects a company's prospects over 12-18 months. C) A Sell rating is assigned when we believe the stock price more than adequately reflects a company's prospects over 12-18 months. Other Disclosures Other Disclosures The information contained herein is based upon sources believed to be reliable but is not guaranteed by us and is not considered to be all inclusive. It is not to be construed as an offer or the solicitation of an offer to sell or buy the securities mentioned herein. Aegis Capital Corp., its affiliates, shareholders, officers, staff, and/or members of their families, may have a position in the securities mentioned herein, and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the Firm from time to time in the open market or otherwise. Opinions expressed are our present opinions only and are subject to change without notice. Aegis Capital Corp. is under no obligation to provide updates to the opinions or information provided herein. Additional information is available upon request. The common stock of the subject company in this report may not be suitable for certain investors based on their investment objectives, degree of risk, as well as their financial status. © Copyright 2020 by Aegis Capital Aegis Capital Corp. (212) 813-1010 810 Seventh Avenue, 18th Floor New York, New York 10019 VistaGen Therapeutics, Inc. October 8, 2020